BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2164 related articles for article (PubMed ID: 20942833)

  • 1. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy.
    Hsu CY; Wildhagen MF; Van Poppel H; Bangma CH
    BJU Int; 2010 Jun; 105(11):1536-40. PubMed ID: 19912180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors.
    Joniau S; Hsu CY; Gontero P; Spahn M; Van Poppel H
    Scand J Urol Nephrol; 2012 Jun; 46(3):164-71. PubMed ID: 22364377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
    Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
    J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
    Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
    Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
    Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
    BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Algorithm for selecting men for pelvic lymph node dissection (PLND) during radical prostatectomy based on clinical risk factors in an Australian population.
    Sengupta S; Weerakoon M; Sethi K; Ischia J; Webb DR
    BJU Int; 2012 Apr; 109 Suppl 3():48-51. PubMed ID: 22458494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
    Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
    Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
    Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
    Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 109.